Laura Q. Chow, MD photo

Laura Q. Chow, MD

Professor, Department of Medicine, Division of Oncology
Associate Director, Phase 1 Program

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E CE2-128
Seattle, WA 98109

Admin Contact

Carly Zipper

Specialty / Expertise

Head, Neck, Lung, and Thyroid Cancer

Research Interests

Lung Cancers
Head & Neck Cancers
Esophageal Cancers
Early Phase Clinical Trials

Current Research Projects

A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake.  NCCN LOI Primary Investigator.  University of Washington. Role: Principal Investigator, Investigator Initiated Study. 

A Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist, in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN). Principal Investigator, Investigator Initiated Study.  Currently enrolling.

Immunologic Correlative Studies for a Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist, in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN).  Role: Principal Investigator (Investigator-Initiated Study) in collaboration with Mary Nora Disis.

Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (H3E-MC-S132).  Principal Investigator, currently enrolling.

A phase I, multicenter, open-label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase(ALK). Principal Investigator. Currently enrolling.

A Phase 1 Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells for Intratumoral Injection in Patients with Solid tumors.  Aided in study protocol writing and development.  Principal Investigator. Pending Initiation Spring 2012.

A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).  Principal Investigator.  Study Opening  March 2012.

An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-small Cell Lung Cancer (NSCLC). Principal Investigator.  Study Opening planned May 2012.

A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients with Advanced Malignant Solid Tumors.  Principal Investigator. Phase I Program Study. Study Opening planned March 2012.

A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumor.  Phase I Program Main Coinvestigator – Non-Small Cell Lung Cancer Cohort and Expansion.  Highest NSCLC enrollment site. 


Dr. Chow received her MD from the University of British Columbia, Vancouver BC, Canada. She completed her Internal Medicine Residency at the University of Alberta, Edmonton AB, Canada. She was a Medical Oncology Fellow at the University of Calgary/Tom Baker Cancer Center, Calgary, Canada and a Phase I Clinical Trail and Drug Development Fellow at the University of Colorado, Denver, CO.

Selected Publications

Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao R, Camidge DR. Sunitinib in combination with pemetrexed for the treatment of advanced solid malignancies – results of a phase I dose-escalation study.  Cancer Chemother Pharmacol. 2011 Oct 12. [Epub ahead of print]

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin and Charles C. Williams, Jr.  Small Cell Lung Cancer – NCCN guidelines. J Natl Compr Canc Netw 2011;9:1086-1113

Breitbach CJ, Burke J, Jonker D,  Stephenson J, Haas A, Chow L, Nieva J, Hwang T, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Je J, Lee Y, Parato K,  Diallo J, Fenster A, Daneshmand M, Bell JC, Kirn DH. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358.

Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQM, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG.   A Phase I, Pharmacological, and Biological Study of IMC-1121B, a Fully-Human IgG1 Monoclonal Antibody, that Targets the Vascular Endothelial Growth Factor Receptor-2.  Journal of Clinical Oncology.  February 10, 2010 vol. 28 no. 5 780-787. 

Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O’Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG.  Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Malignancies: Results of a Phase 1 and PK Study.  Journal of Clinical Oncology.  September 10, 2009 vol. 27 no. 26 4413-4421.

Lieu C*, Chow LQ*, Pierson AS, Eckhardt SG, O¹Bryant CL, Morrow M, Tran ZV, Wright JJ,  Gore L..  Phase I Study of Bortezomib, Etoposide and Carboplatin in Patients with Advanced Solid Tumors Refractory to Standard Therapy.   Invest New Drugs. 2009 Feb;27(1):53-62.
*[acknowledged as co-first author –with equal contribution in writing manuscript]

O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. Dose-Ranging Study of the Pharmacokinetics and Pharmacodynamics of the Selective Apoptotic Antineoplastic Drug (SAAND), OSI-461, in Patients With Advanced Cancer, in the Fasted and Fed State.  Cancer Chemotherapy and Pharmacology. 2009 Feb;63(3):477-89.

Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG.  A Phase I Study of PI-88 and Docetaxel in Patients with Advanced Malignancies. Cancer Chemotherapy and Pharmacology. 2008 Dec;63(1):65-74.

Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L.  A Phase I Safety, Pharmacological, and Biological Study of the Farnesyl Protein Transferase Inhibitor, Lonafarnib (SCH 663366), in Combination with Cisplatin and Gemcitabine in Patients with Advanced Solid Tumors.  Cancer Chemotherapy and Pharmacology. 2008 Sep;62(4):631-46.

Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. A Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Small Molecule MEK1/2 Inhibitor AZD6244 (ARRY-142886) in Patients with Advanced Cancers.  Journal of Clinical Oncology. 2008 May 1;26( 13) :2139-46.

Powell E, Chow LQM.  BLP-25 Liposomal Vaccine: A Promising Potential Novel Therapy in Non-small cell Lung Cancer. Expert Review of Respiratory Medicine, Future Drugs.  February 2008 vol 2, no 1 pp 37-45.

Chow LQ,  Chen C, David Raben D.  EGFR Inhibitors and Radiation in HNSCC. Current Cancer Therapy Reviews.  November 2007, vol 3, Issue no 4. pp. 255-266.

Chow LQ, Eckhardt SG.  Sunitinib:  From Rational Design to Clinical Efficacy.  Journal of Clinical Oncology. Vol 25, No 7 (March 1), 2007: pp. 884-898.
* acknowledged by the editor of JCO in 2011 as one of the top cited articles in 2007 and one of the 50 top cited articles in JCO with over 134 citations as of January 2011.

Chow LQM, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, Stewart DA. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplantation 36, 591-596, 01 Oct 2005.

Chow LQ, Lai R, Dabbagh L, Belch A, Young JD, Cass CE, Mackey JR. Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry. Modern Pathology 2005; 18 (issue 4): 558-564.
PEER-REVIEW PAPERS PUBLISHED in refereed journals continued

Chow LQ, Brown N, Kunimoto D. Invasive Pulmonary Aspergillosis in a Cystic Fibrosis Patient Cured with Voriconazole. Clinical Infectious Disease. 2002; 35: e106-110.

Last updated: March 2012